BTMD · Biote Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $192.22M | $197.19M | $185.36M | $139.40M | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | - | - | - | - | - |
| SG&A | $101.81M | $107.45M | $98.83M | $49.05M | - |
| Total Operating Expenses | - | - | - | - | - |
| D&A | $3.67M | $3.57M | $2.99M | $1.40M | - |
| Operating Income | $35.55M | $31.61M | $28.66M | ($60.72M) | ($3.32M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $5.99M | $970.0K | $2.68M | $388.0K | $0 |
| Net Income | $27.05M | $3.16M | $3.32M | ($969.0K) | $11.11M |
| EPS - Basic | $0.86 | $0.09 | $0.13 | ($0.12) | - |
| EPS - Diluted | $0.74 | $0.09 | $0.13 | ($0.12) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $24.12M | $39.34M | $89.00M | $79.23M | $130.4K |
| Accounts Receivable | $6.87M | $7.63M | $6.81M | $6.95M | - |
| Inventory | $19.06M | $14.85M | $17.31M | $11.18M | - |
| Accounts Payable | $6.83M | $5.81M | $4.16M | $4.11M | $0 |
| Current Assets | $54.67M | $68.13M | $122.34M | $101.18M | $451.6K |
| Total Assets | $107.61M | $122.37M | $155.29M | $111.64M | $318.03M |
| Current Liabilities | $44.99M | $51.51M | $22.21M | $18.77M | $2.27M |
| Long-term Debt | $95.78M | $101.20M | $106.63M | $112.09M | - |
| Total Liabilities | $158.01M | $224.57M | $191.84M | $169.92M | $23.16M |
| Stockholders' Equity | ($58.54M) | ($105.93M) | ($29.40M) | ($44.46M) | ($22.63M) |
| Retained Earnings | ($49.55M) | ($100.30M) | ($29.39M) | ($44.46M) | $0 |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $35.19M | $45.24M | $26.88M | ($9.16M) | ($1.37M) |
| Investing Cash Flow | ($6.86M) | ($18.80M) | ($2.71M) | ($1.84M) | ($317.50M) |
| Financing Cash Flow | ($43.55M) | ($76.08M) | ($14.38M) | $63.46M | $319.00M |
| CapEx | $5.01M | $6.43M | $359.0K | $1.45M | - |
| Free Cash Flow | $30.18M | $38.81M | $26.52M | ($10.61M) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | 18.5% | 16.0% | 15.5% | -43.6% | - |
| EBITDA margin | 20.4% | 17.8% | 17.1% | -42.6% | - |
| Net margin | 14.1% | 1.6% | 1.8% | -0.7% | - |
| Free cash flow margin | 15.7% | 19.7% | 14.3% | -7.6% | - |
| FCF / Net income | 1.12 | 12.29 | 8.00 | 10.94 | - |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | 53.0% | 54.5% | 53.3% | 35.2% | - |
| Effective tax rate | 18.1% | 23.5% | 44.7% | - | 0.0% |
| Return on assets | 25.1% | 2.6% | 2.1% | -0.9% | 3.5% |
| Return on equity | -46.2% | -3.0% | -11.3% | 2.2% | -49.1% |
| Return on invested capital | 78.2% | - | 20.5% | -70.9% | - |
| Liquidity | |||||
| Current ratio | 1.22 | 1.32 | 5.51 | 5.39 | 0.20 |
| Quick ratio | 0.79 | 1.03 | 4.73 | 4.80 | 0.20 |
| Cash ratio | 0.54 | 0.76 | 4.01 | 4.22 | 0.06 |
| Leverage | |||||
| Debt / Equity | -1.64 | -0.96 | -3.63 | -2.52 | - |
| Debt / Assets | 0.89 | 0.83 | 0.69 | 1.00 | - |
| Debt / EBITDA | 2.44 | 2.88 | 3.37 | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | -1.84 | -1.16 | -5.28 | -2.51 | -14.05 |
| Liabilities / Assets | 1.47 | 1.84 | 1.24 | 1.52 | 0.07 |
| Efficiency | |||||
| Asset turnover | 1.79 | 1.61 | 1.19 | 1.25 | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | 13d | 14d | 13d | 18d | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | 3.5x | 68.7x | 38.0x | - | - |
| P / B | - | - | - | - | - |
| P / S | 0.5x | 1.1x | 0.7x | 0.2x | - |
| EV / EBITDA | 4.3x | 7.8x | 4.6x | - | - |
| Growth | |||||
| Revenue growth (YoY) | -2.5% | 6.4% | 33.0% | - | - |
| Revenue CAGR (3y) | 11.3% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 12.5% | 10.3% | - | -1728.0% | - |
| Net income growth (YoY) | 756.7% | -4.8% | - | - | - |
| EPS growth (YoY) | 722.2% | -30.8% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -22.2% | 46.3% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 44.7% | -260.3% | 33.9% | -96.5% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$384.44M totalProduct Revenue$186.92M · 48.6%
Pellet Procedures Product Revenue$137.04M · 35.6%
Dietary Supplements$42.88M · 11.2%
Service Revenue$5.29M · 1.4%
Disposable Trocars Product Revenue$4.85M · 1.3%
Other Service Revenue$2.86M · 0.7%
Shipping Fees And Other Product Revenue$2.15M · 0.6%
Contract Term Services Revenue$1.36M · 0.4%
Training Service Revenue$1.08M · 0.3%
Geographic
$191.20M totalUS$191.20M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
2.33
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing biote Corp. against the 5 most active filers in the same SIC group.